MASTER COPY

REPUBLIC OF THE PHILIPPINES
DEPARTMENT OF FINANCE
BUREAU OF CUSTOMS
MANILA 1099
South Harbor, Gate 3, Port Area, Manila

May 14, 2019

CUSTOMS MEMORANDUM CIRCULAR
NO. 125-2019

To : All District / Port Collectors
All Others Concerned

SUBJECT: **Monitoring of Counterfeit Drug Products (Rabies Vaccines and Serum)**

Attached is a copy of the letter dated February 20, 2019 from Nela Charade G. Puno, Rph, Director General, Food and Drug Administration (FDA), requesting vigilance from the Bureau of Customs (BOC) on the Drug Products bearing the enumerated brands and tabulated Batch numbers / Lot numbers.

For your information and guidance.

For records purposes, please confirm the dissemination of this Circular throughout your offices within fifteen (15) days from receipt thereof.

REY LEONARDO B. GUERRERO
Commissioner, BOC

BOC-09-00571

Attachment: as stated

CMC 25-2019 P.2

MASTER COPY

Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

REPUBLIC OF THE PHILIPPINES
BUREAU OF CUSTOMS
OFFICE OF THE DEPUTY COMMISSIONER
ASSESSMENT & OPERATIONS COORDINATING GROUP
RECEIVED
BY: DENNIS W
DATE: 27 MAR 2019
TIME: 3:57 PM

20 February 2019

MR. REY LEONARDO B. GUERRERO
Bureau of Customs Commissioner
G/F OCOM Building, 16th Street,
South Harbor, Port Area,Manila

BOC-09-00571

BUREAU OF CUSTOMS
MESSAGE CENTER
RECEIVED
MAR 27 2019
BY: kelly TIME: 9:48

Dear **Mr. Guerrero,**

The Food and Drug Administration, Center for Drug Regulation and Research would like to formally inform your good office on the timely issues on Counterfeit Drug Products specifically Rabies Vaccines and Serums presently circulating in the Philippine market and were distributed in Hospitals, Pharmacies, Clinics and Health Centers. A number of patients were exposed to the falsified drug products and may cause adverse effects to those administered with these products. FDA would like to ask your team to be vigilant on the following Drug Products bearing these Batch numbers / Lot numbers:

	Verorab		
Formulation (dosage form, strength)	5 vials x 0.5 ml (1 dose) + 5 ampoules solvent Powder and solvent for suspension for injection	Powder and solvent for suspension for injection 1 dose of powder in a vial (≥2.5 IU) and 0.5mL of solvent in a prefilled syringe	Powder and solvent for suspension for injection 1 dose of powder in a vial (≥2.5IU) and 0.5ml of solvent in prefilled syringe)
Claimed Registration No.	BR-220	BR-220	BR-230
Batch number/Lot no. (box)	Batch no: H1833	Lot no: N1E353M	Lot no: H 1742
Batch number/Lot no. (vial)	Batch no: H1833	Lot no: N1E35	Lot no: H1742
Batch number/Lot no. (solvent)	Batch no: H7720 (ampoule)	Lot no: M0027 (pre-filled syringe)	Lot no: H7720 (vial)
Manufacturing date	03 NOV 17	23 MAY 16	30 NOV 16
Expiry date	09 OCT 17	04-2019	10 - 2019

cmc 125 - 2019 R3

MASTER COPY

Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

	Verorab		
Formulation (dosage form, strength)	Powder and solvent for suspension for injection 1 dose of powder in a vial (≥2.5IU) and 0.5ml of solvent in prefilled syringe)	Powder and solvent for suspension for injection 1 dose of powder in a vial (≥2.5IU) and 0.5ml of solvent in prefilled syringe)	5 vials x 0.5 ml (1 dose) + 5 ampoules solvent Powder and solvent for suspension for injection
Claimed Registration No.	BR-230	BR-220	Not indicated
Batch number/Lot no. (box)	Lot no: H 1833	Lot no: H1833	Lot no: N1J75V
Batch number/Lot no. (vial)	Lot no: H1833	Lot no: H1833	N/A
Batch number/Lot no. (solvent)	Lot no: H7720 (vial)	Lot no: H7720 (vial)	N/A
Manufacturing date	30 NOV 17	30 NOV 17	28092017
Expiry date	10 - 2021	10 - 2021	12-2020

	Speeda	
Formulation (dosage form, strength)	5 vials of 2.5 IU Freeze-dried Powder for Injection + 5 ampoules of 0.5mL of solvent	5 vials of 2.5 IU Freeze-dried Powder for Injection + 5 ampoules of 0.5mL of solvent
Claimed Registration No.	BR-669	BR-669
Batch number/Lot no. (box)	Batch no:201803067	Batch no: 201708295
Batch number/Lot no. (vial)	Batch no: 201803067	Batch no: 201708295
Batch number/Lot no. (solvent)	Batch no: 201803067 (ampoule)	Batch no: 201770520-1 (ampoule)
Manufacturing date	03/15/2018	08/31/2017
Expiry date	03/14/2021	08/30/2020

OFFICE OF THE DIRECTOR
IAS
RECEIVED
By:
Date: 03/28/19
Time: 02:13 PM

Civic Drive, Filinvest City, Alabang 1781 Muntinlupa, Philippines
Trunk Line +63 2 857 1900
Fax +63 2 807 0751
Website: www.fda.gov.ph
Email: info@fda.gov.ph

CMC 125-2019 p.4

MASTER COPY

Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

	Equirab		
Formulation (dosage form, strength)	ANTI-RABIES SERUM (EQUINE) (EQUIRAB) 200 iu/mL (1000 IU/5mL	ANTI-RABIES SERUM (EQUINE) (EQUIRAB) 200 iu/mL (1000 IU/5mL)	ANTI-RABIES SERUM (EQUINE) (EQUIRAB) 200 iu/mL (1000 IU/5mL
Claimed Registration No.	BR-676	BR-676	BR-676
Batch number/Lot no. (box)	A02717008	A02718008	A02718012
Batch number/Lot no. (vial)	A02717008	A02718008	A02718012
Manufacturing date	3/18	03/18	07/18
Expiry date	2/20	02/20	06/20

The Food and Drug Administration is looking forward to your support and cooperation on this matter. Together, let us take an extra mile to secure the safety and wellness of the General Public.

NELA CHARADE G. PUNO, RPh
Director General
Food and Drug Administration

20190213135424